MSI-H Clinical Trials

5 recruiting

MSI-H Trials at a Glance

18 actively recruiting trials for msi-h are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Beijing. Lead sponsors running msi-h studies include Akeso, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), and 7 Hills Pharma, LLC.

Browse msi-h trials by phase

Treatments under study

About MSI-H Clinical Trials

Looking for clinical trials for MSI-H? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MSI-H trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MSI-H clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Advanced Solid Tumors CancerMSI-H Cancer
Nimbus Wadjet, Inc.134 enrolled22 locationsNCT06898450
Recruiting
Phase 3

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

MSI-H/dMMR Colorectal CancerResectable Colon Cancer
Akeso386 enrolled1 locationNCT07412613
Recruiting
Phase 2

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Phase 3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Gastric CancerMetastatic CancerAdvanced Cancer+1 more
Centre Leon Berard132 enrolled6 locationsNCT06346197
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled6 locationsNCT07403721
Recruiting
Phase 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Endometrial CancerAdvanced Solid TumorMetastatic Solid Tumor+1 more
MOMA Therapeutics132 enrolled14 locationsNCT06974110
Recruiting
Phase 1Phase 2

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

MelanomaAdvanced Solid TumorMetastasis+5 more
7 Hills Pharma, LLC126 enrolled5 locationsNCT06362369
Recruiting
Phase 1Phase 2

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Endometrial CancerAdvanced Solid TumorsMSI-H or dMMR Advanced Solid Tumors+4 more
Eikon Therapeutics160 enrolled10 locationsNCT07262619
Recruiting

Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer

Colo-rectal Cancer (dMMR/MSI-H CRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled1 locationNCT07352280
Recruiting
Phase 2

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust50 enrolled9 locationsNCT06250036
Recruiting
Phase 1

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

Liver CancerEsophageal CancerGastric Cancer+9 more
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)18 enrolled1 locationNCT07001592
Recruiting
Phase 2

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

MelanomaHead and Neck NeoplasmsMSI-H Cancer
University Medical Center Groningen97 enrolled1 locationNCT05483400
Recruiting
Phase 1Phase 2

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University28 enrolled1 locationNCT05426005
Recruiting
Phase 3

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
Centre Hospitalier Universitaire Dijon68 enrolled1 locationNCT06762405
Recruiting
Phase 2

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Gastric CancerColon CancerMSI-H+1 more
Peking University38 enrolled1 locationNCT06580574
Recruiting
Phase 1Phase 2

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal CancerRadiotherapyAnti-PD-1 Antibody+2 more
West China Hospital20 enrolled1 locationNCT04636008
Recruiting
Phase 3

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H
Innovent Biologics (Suzhou) Co. Ltd.360 enrolled1 locationNCT05890742
Recruiting
Phase 2

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

MSI-H Solid Malignant Tumor
Shanghai Henlius Biotech108 enrolled33 locationsNCT03941574